Effect of Ezetimibe  + Pitavastatin on Cardiovascular Outcomes in Patients with ST-segment Elevation Myocardial Infarction (From the HIJ-PROPER Study)

Aggressive lipid-lowering therapy with statins is the generally accepted approach for treating patients with acute coronary syndrome (ACS).1,2 Recently, the findings from studies of patients with ACS who were administered intensive lipid-lowering therapy involving non-statin drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9, that is, PCSK9, inhibitors, showed improved clinical outcomes.3,4 We published results from the Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER) study, a randomized controlled trial which tested the efficacy of intensive lipid-lowering therapy by statin and ezetimibe and compared it with standard lipid-lowering therapy by statin monotherapy in ACS patients5.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research